Bone histomorphometry of transiliac paired bone biopsies after 6 or 12 months of treatment with oral strontium ranelate in 387 osteoporotic women. Randomized comparison to alendronate
Journal of Bone and Mineral Research, 08/20/2013Chavassieux P et al.
Preclinical studies indicate that strontium ranelate (SrRan) induces opposite effects on bone osteoblasts and osteoclasts, suggesting that SrRan may have a dual action on both formation and resorption. By contrast, alendronate (ALN) is a potent antiresorptive agent. This large controlled paired–biopsy study over one year shows that the bone formation remains higher with a lower diminution of the bone remodeling with SrRan versus ALN. From these results SrRan did not show a significant anabolic action on bone remodeling.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.